CivicaScript® Introduces Affordable Cancer Treatment
In a significant development for cancer treatment accessibility, CivicaScript®, LLC, has launched its low-cost generic capecitabine. This innovative step aims to address the financial burden faced by many patients undergoing treatment for various cancers such as colorectal, breast, and pancreatic cancer.
Revolutionizing Cancer Drug Pricing
Capecitabine, classified as a nucleoside metabolic inhibitor, is now available in 500 mg film-coated tablets at a price of just $63 per bottle containing 120 tablets. This pricing structure is a part of CivicaScript's commitment to affordability, allowing pharmacies to charge a maximum of $84, which corresponds to their MaxRP (Maximum Retail Price) policy.
Cost Savings for Patients
Notably, CivicaScript's pricing strategy could offer estimated savings of approximately $1,500 per month compared to traditional pharmacy benefit managers (PBM) rates. This reduction is particularly impactful during the deductible phase of health insurance, where patients usually bear the entire cost of their medications.
Transparent Business Model
CivicaScript's approach revolves around transparency and collaboration, ensuring that all parties involved—from manufacturers to healthcare providers—are aligned on the goal of providing the lowest sustainable costs. CivicaScript President Brent J. Eberle stated, "The momentum we're creating with our transparent business model is proving to be both successful and sustainable. We're aligning all stakeholders to prioritize the lowest sustainable cost, which means lower prices for patients and cost savings throughout the system.”
Impact of Efficiency and Clarity
By implementing its MaxRP policy, CivicaScript allows patients and healthcare professionals to assess costs effectively, assuring fair charges through an easily scannable QR code on the product's label. This integration of technology promotes clarity and accountability in pricing.
Addressing High Medication Costs
The choice to introduce capecitabine stems from the pressing demand for affordable cancer medications amidst rising healthcare costs. Many patients either ration their prescriptions or forgo them altogether due to high prices, a concern validated by multiple studies on medication costs and adherence rates.
About CivicaScript
As a nonprofit organization, CivicaScript is committed to enhancing the transparency of the drug supply chain. It strives to make quality generic medicines available and affordable for all, promoting overall health and welfare in the community. For further information about CivicaScript's mission, visit their website to learn more about their initiatives.
Manufacturer Partnerships
CivicaScript collaborates with various manufacturers to produce affordable generic drugs, thereby ensuring that they can extend the cost savings directly to patients through their partnerships with pharmacies and payers nationwide.
Frequently Asked Questions
What is CivicaScript®?
CivicaScript® is a nonprofit company that focuses on making low-cost generic medicines accessible to patients in the U.S.
What type of cancer is capecitabine used for?
Capecitabine is indicated for treating cancers such as colorectal, breast, gastric, and pancreatic cancers.
How much can patients save with CivicaScript® capecitabine?
Patients may save approximately $1,500 per month compared to pricing at traditional pharmacies affiliated with pharmacy benefit managers.
What does CivicaScript’s MaxRP policy entail?
The MaxRP policy sets a maximum retail price for medications, ensuring that pharmacies provide fair pricing and giving patients the ability to verify those prices.
How does CivicaScript ensure transparency in pricing?
CivicaScript utilizes a QR code on medication labels, allowing consumers to confirm they are charged no more than the maximum retail price established by the company.
